Dongsheng Tu

Title: Professor
E-Mail: dtu@ctg.queensu.ca
Webpage: http://meds.queensu.ca/qcri/mentors/ri_dt.htm

Degrees

B. Sc. (University of Science and Technology of China)

Ph. D. (Medical University of South Carolina)

Research Statement

I am a senior biostatistician in the NCIC Clinical Trials Group of the Queen’s University Cancer Research Institute and a professor of biostatistics in the Department of Community Health and Epidemiology with a cross-appointment in the Department of Mathematics and Statistics.  As a key member of research teams which conduct clinical trials in cancer therapy, supportive care and prevention across Canada and internationally, I am responsible for the design, management, and analysis of these trials.  I also maintain an independent research program which focuses on the development of statistical theory and methods for the design and analysis of cancer clinical trials.

Selected Recent Publications

(underlined are students supervised; full publication list can be found at http://scholar.google.com/citations?user=M_O4ds4AAAAJ&hl=en )

1.       Chen, B. E., Jiang, W., Tu, D. A Hierarchical Bayes Model for Biomarker Subset Effects in Clinical Trials, Computational Statistics and Data Analysis, 71 (2014), 324-334.

2.       Jin, H., Zhao, N., Tu, D. Weighted Rank Tests for Non-inferiority Hypotheses Based on Paired Survival Times, Journal of Biopharmaceutical Statistics, 23 (2013), 432–446.

3.       Yan, Y., Li, X., Blanchard, A., Bramwell, V. H. C., Pritchard, K. I., Tu, D., Shepherd, L., Myal, Y., Penner, C., Watson, P. H., Leygue, E., Murphy, L.C. Expression of Both Estrogen Receptor-beta 1 (ER-β1) and Its Co-regulator Steroid Receptor RNA Activator Protein (SRAP) are Predictive for Benefit From Tamoxifen Therapy in Patients with Estrogen Receptor-alpha (ER-α) Negative Early Breast Cancer (EBC), Annals of Oncology, 24 (2013), 1986-1993.

4.       Jiang S, Tu D. Inference on the Probability P(T1<T2) as a Measurement of Treatment Effect under a Density Ratio Model and Random Censoring, Computational Statistics and Data Analysis, 56 (2012), 1069-1078.

5.       Song H, Peng P, Tu D. A New Approach for Joint Modelling of Longitudinal Measurements and Survival Times with a Cure Fraction, Canadian Journal of Statistics, 40 (2012), 207-224.

6.       Jin H, Zhao N, Tu D. Nonparametric Confidence Intervals for the Ratio of Marginal Hazard Rates of Paired Survival Times, Biometrical Journal, 54 (2012), 197–213.

7.       Li X, Wu Y, Tu D. Jackknifed Random Weighting for Cox Proportional Hazard Model, SCIENCE CHINA Mathematics, 55 (2012), 775-786.

8.       Liu X, Peng Y, Tu D, Liang H. Variable Selection in Semiparametric Cure Models based on Penalized Likelihood, with Application to Breast Cancer Clinical Trials, Statistics in Medicine, 31 (2012), 2882–2891.

9.       Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer Term Outcomes of Letrozole Versus Placebo after 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Cross-over, Journal of Clinical Oncology, 30 (2012), 718-721.

10.    Cheang MCU, Voduc D, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MTW, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial, Clinical Cancer Research, 18 (2012), 2402-2412.

11.    Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50 Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen, Clinical Cancer Research, 18 (2012), 4465-4472.

12.    Pritchard KI, Munro A, O’Malley FP, Tu D, Li X, Levine MN, Shepherd LE, Chia S, Bartlett JMS. Chromosome 17 Centromere (CEP17) Duplication as a Predictor of Anthracycline Response:  Evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial, Breast Cancer Research and Treatment, 131 (2012), 541-551.

13.    Hertel PB, Tu D, Ejlertsen B, Jensen M, Balslev E, Jiang S, O’Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients, Breast Cancer Research and Treatment, 132 (2012), 225-234.

14.    Li, X., Chen, J., Wu, Y., Tu, D. Constructing Confidence Regions with High Order Precision by Adjusting Exponential Empirical Likelihood, Statistica Sinica, 21 (2011), 1767-1783.

15.    Luo, Y., Tan, X. and Tu, D. Assessing Similarity of Two Survival Functions Based on Censored Data and the Trimmed Mallows Distance, In Theoretical Advances and Applications in Operations Research-Modeling Non-normal Phenomena (Ed. K. Tan and J. Gani), 2011, 33-46, Kyushu University Press, Fukuoka, Japan.

16.    Sun, X., Peng, P. and Tu, D. Phase II Cancer Clinical Trials with a One-sample Log-rank test and Its Corrections Based on Edgeworth Expansion, Contemporary Clinical Trials, 32 (2011), 108–113.

17.    Jiang, S., Tu, D. Empirical Likelihood Confidence Intervals for Ratio of Hazard Rates under Right Censorship, Statistics and Its Interface, 3 (2010), 455-464.

18.    Tan, X., Takahara, G., Tu, D. Optimal Two-Stage Design for the Phase II Cancer Clinical Trials with Responses and Early Progression as Co-primary Endpoints, Statistics in Biopharmaceutical Research, 2 (2010), 348-354.

19.    Zhu, L., Tan, X. and Tu, D. Testing the Homogeneity of Two Survival Functions against a Mixture Alternative Based on Censored Data, Communications in Statistics - Simulation and Computation, 39 (2010), 767–776.

20.    Cheng, M. Y., Qiu, P., Tan X., Tu, D. Confidence Intervals for the First Crossing Point of Two Hazard Functions, Lifetime Data Analysis, 15 (2009), 441-454.

21.     Li, X., Wu, Y., Tu, D. Adjusted Empirical Likelihood in Cox Proportional Hazard Model, Journal of University of Science and Technology of China, 39 (2009), 1253-1257.

22.    Dhani, N., Tu, D., Sargent, D., Seymour, L., Moore, M. J. Alternate Endpoints for Screening Phase II Studies, Clinical Cancer Research, 15 (2009), 1873-82.

23.    Li, X., Wu, Y., Tu, D. A Bartlett Correction for Wald Test in Cox Regression Model, Statistics and Probability Letters, 78 (2008), 2614-2622.

24.    Goffin, J. R. and Tu, D. Phase II Stopping Rules Employing Response Rates and Early Progression, Journal of Clinical Oncology, 26 (2008), 3715-3720.

25.    Liu, S. and Tu, D. On the Applications of Fisher's Least Significant Difference (LSD) Procedure in Three-Arm Clinical Trials with Survival Endpoints, Drug Information Journal, 42 (2008), 81-91.

26.    Tu, D. Under-smoothed Kernel Confidence Intervals for the Hazard Ratio Based on Censored Data, Biometrical Journal, 49 (2007), 474-483.

27.     Mazumdar, M., Tu, D., Zhou, X. Some Design Issues of Strata Matched Non-randomized Studies with Survival Outcomes, Statistics in Medicine, 25 (2006), 3949-3959.

28.    Liu, J., Tu, D., Dancey, J., Reyno, L., Pritchard, K., Pater, J., Seymour, L. Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: A NCIC CTG Trial MA.19, Breast Cancer Research and Treatment, 100 (2006), 263-271.

29.     Cheng, M., Hall, P., Tu, D. Confidence Bands for Hazard Rate Under Random Censorship, Biometrika, 93 (2006), 357-366.

30.     Tu, D., Chen, J., Shi, P., Wu, Y. A Bartlett Type Correction for Rao's Score Test in Cox Regression Model, Sankyā, 67 (2005), 722-735.

 

Recent Graduate Students (in Maths. and Stats.)

I have supervised/co-supervised students in both the Department of Mathematics and Statistics and the Department of Public Health Sciences at Queen's. Listed below are students from Mathematics and Statistics only.

1. Ruqi Zhang: Analyses of Biomarkers, Quality of Life and Health Preference Data from Cancer Clinical Trials, M. Sc. (2013); Current position: Biostatistician at the University of Glasgow, UK.

2. Hui Song: Joint Modelling of Longitudinal Quality of Life Measurements and Survival Data in Cancer Clinical Trials, Ph. D. (2013); Current position: Lecturer, Dalian University of Technology, China.

3. Yongwei Liu: Quality Control and SAS Programming in the Management and Analysis of Clinical Trial Data, M. Sc (2012); Current position: Biostatistician/SAS programmer at Inflamax Research Inc., Mississauga.

4. Shifang Liu: Statistical Methods for Testing Treatment-Covariate Interactions in Cancer Clinical Trials, Ph. D. (2011); Current position: Associate Director at Biogen Idec, Boston.

5. Yinghua Su: Evaluating Time-Dependent Effects of Breast Cancer Treatment based on Nonparametric Methods and Time-Dependent Cox Models, M. Sc. (2011); Current position: Biostatistician in Health Canada, Ottawa.

6. Shan Jiang: Statistical Inference for the Treatment Effect in Cancer Clinical Trials, Ph. D. (2011); Current position: Manager of Parameter Estimation at Royal Bank of Canada, Toronto.

7. Tinghua Zhang: Resampling Methods for Estimating the Accuracy of Survival Probability Prediction based on Censored Survival Data and Cox Proportional Hazard Model, M. Sc. (2010); Current position: Biostatistician, Ottawa Hospital Research Institute.

8. Xiaoqun Sun: Improvement of One-Sample Log-rank Test Based on Edgeworth Expansion with Application to Phase II Cancer Clinical Trials, M. Sc. (2008); Current position: Clinical Data Analyst at Kingston General Hospital.

9. Liting Zhu: Testing the Homogeneity of Two Survival Functions against a Mixture Alternative Based on Censored Data, M. Sc. 2007; Current position: Biostatistician at NCIC Clinical Trials Group, Kingston, Ontario.

10. Audrey Boruvka: Data-driven Estimation for Aalen’s Additive Risk Model, M. Sc. (2007); Current position: Postdoctoral Research Fellow at University of Michigan.

 

Contact Info

Department of Math & Stats
Jeffery Hall, University Ave.
Kingston, ON Canada, K7L 3N6
Phone: (613) 533-2390
Fax: (613) 533-2964
mathstat@mast.queensu.ca

Search